MarketCapExport financials
ENDRA Life Sciences (NDRA)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
ENDRA Life Sciences Balance Sheet 2025-2011 | NDRA
Brief overview of ENDRA Life Sciences 's assets and capital
The review uses the five latest available annual reports between 2021 and 2025.
Across five reporting periods, assets decreased -70.1%, from $12.9 million to $3.9 million, producing a negative trend.
Funding shifted toward liabilities: they gained -23.8%, compared with -70.1% for assets.
Internal capital represents 58.6% of the balance sheet, previously 83.8%. This is a strong capital position.
Cash exceeds interest-bearing debt, producing net debt of -$270 thousand. The balance sheet therefore carries a net cash position.
The cash share moved from 73.5% to 19.8%. A higher figure generally provides more room in an adverse scenario.
Retained earnings remain negative at -$110.5 million. This may reflect past losses or substantial shareholder distributions, so earnings and buybacks provide important context.
Overall picture
The balance sheet gives no single signal for ENDRA Life Sciences : some indicators are sound, while leverage or capitalization needs attention.
Annual Balance Sheet ENDRA Life Sciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-270 K | -2.65 M | - | -4.37 M | -8.78 M | -6.54 M | -5.47 M | -6.47 M | -5.6 M | 805 K | -19.1 K | -156 K | - | - | - |
Long Term Debt |
363 K | 487 K | - | 366 K | 547 K | 337 K | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
129 K | 96.9 K | 174 K | 152 K | 132 K | 76.5 K | 66.2 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
843 K | 1.29 M | 192 K | 366 K | - | 609 K | 343 K | - | - | - | 1 | - | - | - | - |
Total Current Liabilities |
751 K | 605 K | 903 K | 1.7 M | 1.54 M | 987 K | 2.07 M | 975 K | 848 K | - | - | - | - | - | - |
Total Liabilities |
1.59 M | 1.89 M | 1.1 M | 2.07 M | 2.09 M | 1.6 M | 2.42 M | 975 K | 848 K | 1.38 M | 236 K | 97.6 K | - | - | - |
Retained Earnings |
-110 M | -103 M | -91.9 M | -81.9 M | -68.7 M | -57.3 M | -45.2 M | -27.7 M | -17.9 M | -12.5 M | -9.74 M | -7.46 M | - | - | - |
Total Assets |
3.85 M | 4.45 M | 6.75 M | 9.27 M | 12.9 M | 8.76 M | 7.18 M | 7.22 M | 6.12 M | 491 K | 487 K | 703 K | - | - | - |
Cash and Cash Equivalents |
762 K | 3.23 M | 2.83 M | 4.89 M | 9.46 M | 7.23 M | 6.17 M | 6.47 M | 5.6 M | 145 K | - | - | - | - | - |
Book Value |
2.26 M | 2.56 M | 5.66 M | 7.2 M | 10.8 M | 7.17 M | 4.76 M | 6.25 M | 5.28 M | -894 K | 250 K | 605 K | - | - | - |
Total Shareholders Equity |
2.26 M | 2.56 M | 5.66 M | 7.2 M | 10.8 M | 7.17 M | 4.76 M | 6.25 M | 5.28 M | -894 K | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet ENDRA Life Sciences
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
327 K | 397 K | 429 K | 461 K | 487 K | - | 98.4 K | - | 192 K | 237 K | 281 K | 324 K | 366 K | 434 K | 473 K | 510 K | 547 K | 553 K | 586 K | 252 K | 272 K | 290 K | 272 K | 272 K | 343 K | 343 K | 343 K | 343 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
816 K | 992 K | 758 K | 852 K | 1.29 M | - | 98.4 K | 146 K | 192 K | 237 K | - | - | 366 K | - | - | - | - | - | - | 281 K | 609 K | 628 K | 645 K | 326 K | 343 K | 343 K | 343 K | 343 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
1.65 M | 1.79 M | 1.33 M | 1.42 M | 1.89 M | - | 1.45 M | 1.36 M | 1.1 M | 2.41 M | 2.31 M | 2.16 M | 2.07 M | 2.14 M | 1.98 M | 1.87 M | 2.09 M | 2.16 M | 2.25 M | 1.05 M | 1.6 M | 2.03 M | 1.6 M | 1.6 M | 2.42 M | 2.42 M | 2.42 M | 2.42 M | 975 K | 975 K | 975 K | 975 K | 848 K | 848 K | 848 K | 848 K | 1.38 M | 1.38 M | 1.38 M | 1.38 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-112 M | -107 M | -106 M | -104 M | -103 M | - | -96.9 M | -94.7 M | -91.9 M | -90.5 M | -87.4 M | -84.8 M | -81.9 M | -78.6 M | -75.1 M | -71.5 M | -68.7 M | -65.6 M | -62.9 M | -59.7 M | -57.3 M | -55.1 M | -57.3 M | -57.3 M | -45.2 M | -45.2 M | -45.2 M | -45.2 M | -27.7 M | -27.7 M | -27.7 M | -27.7 M | -17.9 M | -17.9 M | -17.9 M | -17.9 M | -12.5 M | -12.5 M | -12.5 M | -12.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
3.44 M | 1.96 M | 2.81 M | 3.17 M | 4.45 M | - | 10.4 M | 5.06 M | 6.75 M | 7.6 M | 9.24 M | 6.65 M | 9.27 M | 12.3 M | 15.3 M | 10.9 M | 12.9 M | 15.3 M | 17.2 M | 18.9 M | 8.76 M | 5.36 M | 8.76 M | 8.76 M | 7.18 M | 7.18 M | 7.18 M | 7.18 M | 7.22 M | 7.22 M | 7.22 M | 7.22 M | 6.12 M | 6.12 M | 6.12 M | 6.12 M | 491 K | 491 K | 491 K | 491 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
356 K | 794 K | 1.81 M | 2.06 M | 3.23 M | 4.75 M | 6.4 M | 1.13 M | 2.83 M | 3.33 M | 4.82 M | 2.36 M | 4.89 M | 8.02 M | 11.3 M | 7.13 M | 9.46 M | 11.8 M | 14 M | 16.8 M | 7.23 M | 7.23 M | 7.23 M | 7.23 M | 6.17 M | 6.17 M | 6.17 M | 6.17 M | 6.47 M | 6.47 M | 6.47 M | 6.47 M | 5.6 M | 5.6 M | 5.6 M | 5.6 M | 145 K | 145 K | 145 K | 145 K | 19.1 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
1.79 M | 171 K | 1.47 M | 1.75 M | 2.56 M | - | 8.99 M | 3.7 M | 5.66 M | 5.2 M | 6.93 M | 4.5 M | 7.2 M | 10.2 M | 13.3 M | 9.07 M | 10.8 M | 13.2 M | 15 M | 17.9 M | 7.17 M | 3.33 M | 7.17 M | 7.17 M | 4.76 M | 4.76 M | 4.76 M | 4.76 M | 6.25 M | 6.25 M | 6.25 M | 6.25 M | 5.28 M | 5.28 M | 5.28 M | 5.28 M | -894 K | -894 K | -894 K | -894 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
1.79 M | 171 K | 1.47 M | 1.75 M | 2.56 M | 6.6 M | 8.99 M | 3.7 M | 5.66 M | 5.2 M | 6.93 M | 4.5 M | 7.2 M | 10.2 M | 13.3 M | 9.07 M | 10.8 M | 13.2 M | 15 M | 17.9 M | 7.17 M | 7.17 M | 7.17 M | 7.17 M | 4.76 M | 4.76 M | 4.76 M | 4.76 M | 6.25 M | 6.25 M | 6.25 M | 6.25 M | 5.28 M | 5.28 M | 5.28 M | 5.28 M | -894 K | -894 K | -894 K | -894 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of ENDRA Life Sciences , providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Diagnostics research
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Anixa Biosciences
ANIX
|
$ 2.81 | 1.63 % | $ 91.2 K |  USA |
 |
Biodesix
BDSX
|
$ 27.49 | 1.95 % | $ 208 M | USA |
 |
Biomerica
BMRA
|
$ 2.4 | 5.96 % | $ 7 M | USA |
 |
BioNano Genomics
BNGO
|
$ 1.35 | 10.66 % | $ 7.35 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
$ 11.67 | 5.68 % | $ 123 M |  China |
 |
Bioventus
BVS
|
$ 13.22 | 1.85 % | $ 881 M | USA |
 |
CareDx, Inc
CDNA
|
$ 52.37 | 4.21 % | $ 2.79 B | USA |
 |
Celcuity
CELC
|
$ 83.55 | 0.12 % | $ 3.91 B | USA |
 |
Co-Diagnostics
CODX
|
$ 1.14 | 1.79 % | $ 1.52 M | USA |
 |
Charles River Laboratories International
CRL
|
$ 269.48 | 0.06 % | $ 13.4 B | USA |
 |
Castle Biosciences
CSTL
|
$ 33.22 | 2.74 % | $ 963 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
$ 239.32 | 1.83 % | $ 26.6 B | USA |
 |
Danaher Corporation
DHR
|
$ 202.7 | 1.28 % | $ 144 B | USA |
 |
DarioHealth Corp.
DRIO
|
$ 7.1 | 2.31 % | $ 28.3 M |  Israel |
 |
Fulgent Genetics
FLGT
|
$ 20.56 | 0.54 % | $ 633 M | USA |
 |
Guardant Health
GH
|
$ 165.87 | 5.39 % | $ 20.8 B | USA |
 |
ICON Public Limited Company
ICLR
|
$ 169.34 | 0.02 % | $ 13.3 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
$ 509.72 | 0.99 % | $ 41 B | USA |
 |
Illumina
ILMN
|
$ 207.94 | 0.72 % | $ 32.2 B | USA |
 |
IQVIA Holdings
IQV
|
$ 264.81 | 1.16 % | $ 45.5 B | USA |
|
Akumin
AKU
|
- | -17.87 % | $ 25.9 M |  Canada |
 |
Laboratory Corporation of America Holdings
LH
|
$ 314.56 | 0.95 % | $ 26.2 B | USA |
 |
Lantheus Holdings
LNTH
|
$ 100.27 | 0.02 % | $ 6.77 B | USA |
 |
Medpace Holdings
MEDP
|
$ 591.17 | 0.62 % | $ 17.1 B | USA |
 |
Mettler-Toledo International
MTD
|
$ 1 287.94 | 1.01 % | $ 26.5 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
$ 3.74 | 9.36 % | $ 346 M | USA |
 |
NeoGenomics
NEO
|
$ 18.27 | 5.51 % | $ 2.34 B | USA |
 |
Neogen Corporation
NEOG
|
$ 11.87 | 0.72 % | $ 2.58 B | USA |
 |
National Research Corporation
NRC
|
$ 22.14 | 4.83 % | $ 496 M | USA |
 |
Natera
NTRA
|
$ 339.13 | 3.1 % | $ 46.4 B | USA |
 |
OPKO Health
OPK
|
$ 1.55 | 0.38 % | $ 1.16 B | USA |
 |
Pacific Biosciences of California
PACB
|
$ 1.36 | 4.23 % | $ 408 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
$ 25.15 | 2.28 % | $ 23.8 B |  Niderland |
 |
Personalis
PSNL
|
$ 16.3 | 0.52 % | $ 1.45 B | USA |
 |
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | USA |
 |
Senseonics Holdings
SENS
|
$ 8.88 | 1.95 % | $ 371 M | USA |
 |
Neuronetics
STIM
|
$ 2.89 | 5.61 % | $ 191 M | USA |
 |
Thermo Fisher Scientific
TMO
|
$ 611.62 | 0.3 % | $ 231 B | USA |
 |
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | USA |
 |
Twist Bioscience Corporation
TWST
|
$ 136.05 | 6.94 % | $ 8.14 B | USA |
 |
VolitionRx Limited
VNRX
|
$ 0.31 | 0.34 % | $ 39 M |  Singapore |
 |
Waters Corporation
WAT
|
$ 407.54 | 1.67 % | $ 24.3 B | USA |
 |
Heska Corporation
HSKA
|
- | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | USA |
 |
Syneos Health
SYNH
|
- | - | $ 4.46 B | USA |
 |
Meridian Bioscience
VIVO
|
- | - | $ 1.49 B | USA |
 |
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K | Israel |
 |
Renalytix AI plc
RNLX
|
- | 5.66 % | $ 22.7 M |  Britain |
 |
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | USA |